ArticleScientific reports2022

Patients deriving long-term benefit from immune checkpoint inhibitors demonstrate conserved patterns of site-specific mutations.

Daniel R PrincipePubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.